Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Cash from Financing Activities (2020 - 2026)

Cardiol Therapeutics filings provide 2 years of Cash from Financing Activities readings, the most recent being -$10198.9 for Q4 2022.

  • On a quarterly basis, Cash from Financing Activities fell 100.02% to -$10198.9 in Q4 2022 year-over-year; TTM through Dec 2022 was -$41466.2, a 100.06% decrease, with the full-year FY2025 number at $11.1 million, down 19.18% from a year prior.
  • Cash from Financing Activities hit -$10198.9 in Q4 2022 for Cardiol Therapeutics, up from -$10614.8 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $47.0 million in Q4 2021 to a low of -$10614.8 in Q3 2022.